Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASP6282 + itraconazole
- Development stage
- Phase 1
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASP6282 + itraconazole is an investigational combination used in clinical pharmacology studies to assess the drug-drug interaction between ASP6282, a small molecule under development by Astellas Pharma, and itraconazole, a strong CYP3A4 inhibitor and approved antifungal. ASP6282’s mechanism is not disclosed in available public information. The combination is not intended as a therapeutic but is evaluated in healthy subjects to determine the potential PK changes, safety, and tolerability when ASP6282 is administered alone and in the presence of itraconazole.
02
Targets
CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on ASP6282 + itraconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASP6282 + itraconazole.